open access

Vol 15, No 3 (2011)
REVIEV
Published online: 2011-09-01
Get Citation

Telmisartan/amlodipine. Single-pill combination — role in antihypertensive therapy

Zbigniew Gaciong
Nadciśnienie tętnicze 2011;15(3):188-200.

open access

Vol 15, No 3 (2011)
REVIEV
Published online: 2011-09-01

Abstract

Available data suggest that around 80% of patients will require combination therapy to achieve contemporary blood pressure targets, and increasing emphasis is being placed on the practical tasks involved in consistently achieving and maintaining goal BP in clinical practice. Telmisartan/amlodipine is a single-pill combination of agents that has previously proven its efficacy in major clinical trials in subjects with hypertension, high cardiovascular risk and coronary heart disease.
In double blind, randomized trials administration of telmisartan/amlodipine fixed-dose combination (Twynsta) resulted in blood pressure control in 80% of subjects with stage 1 and 2 and 50% of patients with severe stage 3 hypertension. The combination provides rapid reduction in blood pressure achieving 80% of its effect within 2 weeks. Side effects are mild, with very low frequency, with discontinuation rate around 2%. Incidence of peripheral edema was lower with combination therapy than with amlodipine monotherapy. Combination of telmisartan/amlodipine can be used as an initial therapy in subjects with stage 2 or 3 hypertension as well as in patients not controlled on monotherapy.
Arterial Hypertension 2011, vol. 15, no 3, pages 188–200.

Abstract

Available data suggest that around 80% of patients will require combination therapy to achieve contemporary blood pressure targets, and increasing emphasis is being placed on the practical tasks involved in consistently achieving and maintaining goal BP in clinical practice. Telmisartan/amlodipine is a single-pill combination of agents that has previously proven its efficacy in major clinical trials in subjects with hypertension, high cardiovascular risk and coronary heart disease.
In double blind, randomized trials administration of telmisartan/amlodipine fixed-dose combination (Twynsta) resulted in blood pressure control in 80% of subjects with stage 1 and 2 and 50% of patients with severe stage 3 hypertension. The combination provides rapid reduction in blood pressure achieving 80% of its effect within 2 weeks. Side effects are mild, with very low frequency, with discontinuation rate around 2%. Incidence of peripheral edema was lower with combination therapy than with amlodipine monotherapy. Combination of telmisartan/amlodipine can be used as an initial therapy in subjects with stage 2 or 3 hypertension as well as in patients not controlled on monotherapy.
Arterial Hypertension 2011, vol. 15, no 3, pages 188–200.
Get Citation

Keywords

guidelines; goal blood pressure; combination therapy; telmisartan; amlodipine

About this article
Title

Telmisartan/amlodipine. Single-pill combination — role in antihypertensive therapy

Journal

Arterial Hypertension

Issue

Vol 15, No 3 (2011)

Pages

188-200

Published online

2011-09-01

Bibliographic record

Nadciśnienie tętnicze 2011;15(3):188-200.

Keywords

guidelines
goal blood pressure
combination therapy
telmisartan
amlodipine

Authors

Zbigniew Gaciong

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: viamedica@viamedica.pl